부산대학교 도서관

Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon‑like peptide‑1 analogues similar to that of patients from other parts of the world. However, subcutaneous treatment with glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) is limited by their injectable mode of administration. The present review highlights barriers to incretinisation with GLP‑1RAs and the role of first‑in‑class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses. [ABSTRACT FROM AUTHOR]